Skip to content
Company Analysis

InMed Pharmaceuticals Inc. INM

A comprehensive view of key metrics, scores, and financial health for InMed Pharmaceuticals Inc.

Overview of InMed Pharmaceuticals Inc.

INM NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
InMed Pharmaceuticals Inc. (INM), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $1.51, about 0.0% overvalued vs fair value, -40.3% 1Y return, ranked 591/1122 in sector.
Metrics Rev Growth 7.5% ROE -72.1% Gross Margin 34.5%
USD 1.51
-4.43%
(Delayed)
• Vol 90d: 161.8%
52-Week Range
Market Cap
$7.05M
Enterprise Value
$-1.76M
Overall Score
View breakdown
Overall
Growth
Excellent
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Excellent
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 70%
Confidence: 82%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.inmedpharma.com
HQ Vancouver, BC
Employees 13
Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-1
$-1
$0
Current: $1.51

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$4.9M
7.5%%
Gross Profit
$1.7M
55%%
R&D Expense
$2.9M
-11.3%%
Operating Income (EBIT)
$-7.8M
-1.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
57.7%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating InMed Pharmaceuticals Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
24
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
13
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing INM's balance between Growth (52.0%), Profitability (11.0%), and Safety (37.1%). Growth 52% Safety 37% Profitability 11%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

71th percentile vs peers
71
Key Signals
Revenue CAGR 3Y 65.5% 91p Rev Growth YoY 7.5% 57p EPS Growth YoY 58.5% 66p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (65.5%, 91th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Current Ratio in top 20% of peers (6.99, 94th percentile)
  • Quick Ratio in top 20% of peers (6.47, 93th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

15th percentile vs peers
15
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

50th percentile vs peers
51
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for InMed Pharmaceuticals Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.59
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000